Systemic Lupus Erythematosus Diagnosis and Management

Diagnostic Approach

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) recommend serological testing for antinuclear antibodies (ANA), anti-double-stranded DNA (anti-dsDNA), anti-Smith antibodies, complement levels (C3, C4), complete blood count, comprehensive metabolic panel including creatinine, urinalysis with microscopy for proteinuria and cellular casts, and antiphospholipid antibody testing for all patients suspected of having SLE 1, 2, 3
Complement levels (C3 and C4) should be measured at baseline and monitored regularly, as hypocomplementemia indicates active disease and immune complex consumption 1, 2
Complete blood count is necessary to detect cytopenias (thrombocytopenia, leukopenia, autoimmune hemolytic anemia), which are common hematological manifestations requiring specific management 2, 3
Neuropsychiatric manifestations such as headache, seizures, psychosis, or cognitive dysfunction require MRI and EEG to exclude structural brain disease 2, 4

Disease activity indices should be assessed at each visit using validated tools like SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) 1, 3
Regular monitoring every 3 months for high-risk patients (males, juvenile onset, serologically active including anti-C1q antibodies) to detect early organ involvement 2
Serial measurements of anti-dsDNA, C3, C4, complete blood count, creatinine, proteinuria, and urine sediment at each visit to track disease activity 1, 3

Hydroxychloroquine at ≤5 mg/kg real body weight is mandatory for all SLE patients unless contraindicated, as it reduces disease activity, prevents flares, and improves survival 1, 3
The dose should not exceed 5 mg/kg real body weight to minimize retinal toxicity risk, which exceeds 10% after 20 years of continuous use 1, 3
Ophthalmological screening is required at baseline, after 5 years, then yearly using visual fields examination and/or spectral domain-optical coherence tomography 1, 3

For mild disease (skin and joint manifestations without major organ involvement), add methotrexate if hydroxychloroquine and low-dose glucocorticoids are insufficient 3
For moderate disease requiring glucocorticoid-sparing, add azathioprine (particularly suitable for women contemplating pregnancy) or mycophenolate mofetil for renal and non-renal manifestations 2, 3
For severe organ-threatening disease (lupus nephritis, cardiopulmonary, or neuropsychiatric manifestations), initiate cyclophosphamide or mycophenolate mofetil as induction therapy 2, 3

Induction therapy: Mycophenolate mofetil or low-dose cyclophosphamide (Euro-Lupus regimen) are first-line agents with the best efficacy/toxicity ratio 2, 3
Maintenance therapy: Mycophenolate mofetil or azathioprine after achieving initial response 2, 3
Treatment goals include at least partial remission (≥50% reduction in proteinuria to subnephrotic levels and serum creatinine within 10% of baseline) by 6-12 months 1

Low-dose aspirin for patients with antiphospholipid antibodies, those receiving corticosteroids, or those with cardiovascular risk factors 3
Calcium and vitamin D supplementation for all patients on long-term glucocorticoids to prevent osteoporosis 3
Photoprotection with sunscreens to prevent cutaneous flares 3

Belimumab (anti-BAFF antibody) is FDA-approved as add-on treatment for active extrarenal SLE and lupus nephritis when standard therapy is insufficient 3
Rituximab should be considered for organ-threatening disease refractory to standard immunosuppressive agents, particularly for hematological manifestations 2, 3
Anifrolumab (anti-type 1 interferon receptor) is approved for moderate-to-severe extrarenal SLE 3

Do not delay kidney biopsy in suspected lupus nephritis, as histological classification is essential for treatment selection and prognosis 2, 3
Do not use mycophenolate mofetil, cyclophosphamide, or methotrexate in women who are pregnant or contemplating pregnancy; azathioprine, hydroxychloroquine, and prednisolone are safe alternatives 3
Do not attribute all neuropsychiatric symptoms to SLE without excluding infection (especially in immunosuppressed patients), metabolic causes, or medication side effects (steroid-induced psychosis) 2, 4
Do not overlook antiphospholipid antibody syndrome, which requires anticoagulation (warfarin with target INR 2.0-3.0 for first venous thrombosis, 3.0-4.0 for arterial or recurrent thrombosis) in addition to immunosuppression 2, 3, 4

Screen for infections (5-fold increased mortality risk), cardiovascular disease, hypertension, diabetes, dyslipidemia, osteoporosis, and malignancies (especially non-Hodgkin lymphoma) at regular intervals 3
Assess cardiovascular risk in patients with persistent proteinuria, GFR <60 mL/min, and chronic glucocorticoid use, as these are major risk factors 1

Immediately exclude pulmonary embolism, acute lupus pneumonitis, and cardiac tamponade before attributing pleuritic chest pain to lupus serositis; high‑dose glucocorticoids are initiated only after infection has been ruled out. 5

When acute lupus pneumonitis is suspected, obtain a high‑resolution chest CT and start aggressive immunosuppression with intravenous methylprednisolone pulses (250–1000 mg daily for 1–3 days) combined with cyclophosphamide. 5

Measure anti‑dsDNA antibodies, complement C3/C4, complete blood count, CRP, and ESR: low complement and elevated anti‑dsDNA indicate active lupus, whereas an elevated CRP favors infection or serositis. 5, 6

Pulmonary embolism—especially in patients with antiphospholipid antibodies—acute lupus pneumonitis, myocardial infarction (2–10‑fold increased risk in SLE), and infection must be excluded before diagnosing serositis‑related chest pain. 7
Do not rely solely on symptoms; hypocomplementemia and rising anti‑dsDNA support active lupus, while normal complement with high CRP suggests infection or non‑lupus inflammation. 6

At each clinical visit, assess disease activity using validated indices (e.g., SLEDAI) and serial laboratory measurements of anti‑dsDNA, complement levels, complete blood count, and inflammatory markers. 6